LifeSpan Vision Ventures Invests in Matter Bio

Matter Bio expects to initiate clinical trials for one of its programs in the next 12 months, as well as scale-up an already revenue generating program in the single molecule mutation sequencing space. Matter Bio expects to initiate clinical trials for one of its programs in the next 12 months, as well as scale-up an already revenue generating program in the single molecule mutation sequencing space. Dr.Jordan B. Burton, Scientific Analyst at LifeSpan Vision Ventures, stated: "Our...
Comunicato Precedente

next
Comunicato Successivo

next
Preferisci Informazione.News su Google

Matter Bio expects to initiate clinical trials for one of its programs in the next 12 months, as well as scale-up an already revenue generating program in the single molecule mutation sequencing space.

Dr. Jordan B. Burton, Scientific Analyst at LifeSpan Vision Ventures, stated: "Our investment in Matter Bio furthers our mission of supporting companies dedicated to longevity and slowing the key drivers of aging. The company's business model brings academic expertise, efficiency, and scale to pursue the mission of quantifying and reversing DNA damage to prevent diseases of aging and increase healthy lifespan. We are excited to work with such a talented team of pioneers in the genomic space and look forward to seeing how the company can extend healthspan countering critical information loss in the genome."

About Matter Bio
Matter Bio, co-founded with world-class scientists, including George Church PhD. and Jan Vijg PhD., is a holding company that is advancing multiple scientific breakthroughs each targeting a critical juncture of information loss. Its core assets include accurate mutation sequencing, reversing somatic mutations, and clearing pathological cells, including cancer.

For more information, visit https://matterbio.com/.

LifeSpan Vision Ventures Invests in Matter Bio

About LifeSpan Vision Ventures
LifeSpan Vision Ventures is a forward-thinking venture capital firm specializing in investments within the aging and longevity space. Our mission is to support and accelerate the development of innovative therapies that extend healthspan, improve the quality of life for individuals as they age, and address age-related challenges. Through strategic partnerships and investments, we aim to shape a future where aging is met with vitality, resilience, and endless possibilities.

For more information about LifeSpan Vision Ventures, please visit https://www.lifespanvisionventures.com/.

Contact: Harry Robb
mob: +44 7795042764
harry.robb@lifespanvision.com

Photo - https://mma.prnewswire.com/media/2254743/matter_bioworks514x386.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/lifespan-vision-ventures-invests-in-matter-bio-301964920.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili
;